FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2327710931> ?p ?o ?g. }

• W2327710931 abstract "Background In early rheumatoid arthritis (eRA), predictors of clinical response and of radiographic progression would be very useful for optimal targeting of available therapies. Individual biomarkers as well as combinations of biomarkers, such as the MBDA test, can be considered for these purposes. In the SWEFOT study, patients with eRA (symptom duration < 1 year) were started on methotrexate (MTX); at 3 months, responders (DAS28 ≤ 3.2) continued MTX monotherapy and were followed in regular care, whereas non-responders were randomized to receive either triple DMARD therapy or the addition of infliximab.Objectives To study the MBDA score and the levels of the 12 individual biomarkers at baseline (BL) as predictors of clinical response at 3 months and radiographic progression at 1 year in eRA.Methods Analyses were performed for patients from the SWEFOT trial who had BL and 3-month assessments of DAS28 (based on ESR), and the MBDA score and the 12 individual biomarkers at BL; and for a subset of patients who also had radiographs at BL and 1 year time-points (assessed using the Van der Heijde modified Sharp score [SvdH]). Patients with DAS28 > 3.2 at 3 months were considered clinical non-responders, and patients with a change in SvdH > 0 as radiographic progressors (“radiological non-responders”). Group comparisons of biomarkers and MBDA scores were performed by Mann-Whitney U test.Results The results are summarized in the [table][1] below. Clinical non-responders had significantly higher BL values for CRP and IL-6 compared to responders. TNF-R1 and VCAM-1 were significantly lower for non-responders, while other biomarkers and the MBDA did not differ. The patients who progressed radiographically had, at BL, significantly higher MBDA scores, inflammatory biomarkers (CRP, SSA and IL-6), MMP-1, MMP-3 and TNF-R1, as well as a trend towards higher VEGF.![Figure][2] Conclusions In eRA patients treated initially with MTX, individual biomarkers at BL may help identify those patients who are less likely to achieve DAS28 ≤ 3.2 after 3 months of MTX therapy. In addition, the MBDA score and individual biomarkers at BL may identify patients at higher risk for radiographic progression during the first year of therapy.Disclosure of Interest K. Hambardzumyan: None Declared, S. Saevarsdottir: None Declared, R. Bolce Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, K. Forslind: None Declared, S. Ernestam: None Declared, I. Petersson: None Declared, P. Geborek: None Declared, D. Chernoff Shareholder of: Crescendo Bioscience, Consultant for: Crescendo Bioscience, D. Haney Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, E. Sasso Shareholder of: Crescendo Bioscience, Employee of: Crescendo Bioscience, R. van Vollenhoven Grant/research support from: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB, Consultant for: AbbVie, BMS, GSK, MSD, Pfizer, Roche, UCB [1]: #F1 [2]: pending:yes" @default.
• W2327710931 created "2016-06-24" @default.
• W2327710931 creator A5008691315 @default.
• W2327710931 creator A5012009272 @default.
• W2327710931 creator A5015705695 @default.
• W2327710931 creator A5024484324 @default.
• W2327710931 creator A5026988401 @default.
• W2327710931 creator A5031662324 @default.
• W2327710931 creator A5040915422 @default.
• W2327710931 creator A5044687965 @default.
• W2327710931 creator A5079197692 @default.
• W2327710931 creator A5079271373 @default.
• W2327710931 creator A5085603352 @default.
• W2327710931 date "2013-06-01" @default.
• W2327710931 modified "2023-10-01" @default.
• W2327710931 title "FRI0061 Multi-biomarker disease activity (MBDA) score and the 12 individual biomarkers in early rheumatoid arthritis patients relate differentially to clinical response and radiographic progression: results from the swefot trial" @default.
• W2327710931 doi "https://doi.org/10.1136/annrheumdis-2013-eular.1188" @default.
• W2327710931 hasPublicationYear "2013" @default.
• W2327710931 type Work @default.
• W2327710931 sameAs 2327710931 @default.
• W2327710931 citedByCount "3" @default.
• W2327710931 countsByYear W23277109312013 @default.
• W2327710931 countsByYear W23277109312014 @default.
• W2327710931 countsByYear W23277109312018 @default.
• W2327710931 crossrefType "journal-article" @default.
• W2327710931 hasAuthorship W2327710931A5008691315 @default.
• W2327710931 hasAuthorship W2327710931A5012009272 @default.
• W2327710931 hasAuthorship W2327710931A5015705695 @default.
• W2327710931 hasAuthorship W2327710931A5024484324 @default.
• W2327710931 hasAuthorship W2327710931A5026988401 @default.
• W2327710931 hasAuthorship W2327710931A5031662324 @default.
• W2327710931 hasAuthorship W2327710931A5040915422 @default.
• W2327710931 hasAuthorship W2327710931A5044687965 @default.
• W2327710931 hasAuthorship W2327710931A5079197692 @default.
• W2327710931 hasAuthorship W2327710931A5079271373 @default.
• W2327710931 hasAuthorship W2327710931A5085603352 @default.
• W2327710931 hasConcept C126322002 @default.
• W2327710931 hasConcept C141071460 @default.
• W2327710931 hasConcept C168563851 @default.
• W2327710931 hasConcept C185592680 @default.
• W2327710931 hasConcept C1862650 @default.
• W2327710931 hasConcept C2777138892 @default.
• W2327710931 hasConcept C2777226972 @default.
• W2327710931 hasConcept C2777575956 @default.
• W2327710931 hasConcept C2779134260 @default.
• W2327710931 hasConcept C2779722408 @default.
• W2327710931 hasConcept C2781059491 @default.
• W2327710931 hasConcept C2781197716 @default.
• W2327710931 hasConcept C36454342 @default.
• W2327710931 hasConcept C535046627 @default.
• W2327710931 hasConcept C55493867 @default.
• W2327710931 hasConcept C71924100 @default.
• W2327710931 hasConceptScore W2327710931C126322002 @default.
• W2327710931 hasConceptScore W2327710931C141071460 @default.
• W2327710931 hasConceptScore W2327710931C168563851 @default.
• W2327710931 hasConceptScore W2327710931C185592680 @default.
• W2327710931 hasConceptScore W2327710931C1862650 @default.
• W2327710931 hasConceptScore W2327710931C2777138892 @default.
• W2327710931 hasConceptScore W2327710931C2777226972 @default.
• W2327710931 hasConceptScore W2327710931C2777575956 @default.
• W2327710931 hasConceptScore W2327710931C2779134260 @default.
• W2327710931 hasConceptScore W2327710931C2779722408 @default.
• W2327710931 hasConceptScore W2327710931C2781059491 @default.
• W2327710931 hasConceptScore W2327710931C2781197716 @default.
• W2327710931 hasConceptScore W2327710931C36454342 @default.
• W2327710931 hasConceptScore W2327710931C535046627 @default.
• W2327710931 hasConceptScore W2327710931C55493867 @default.
• W2327710931 hasConceptScore W2327710931C71924100 @default.
• W2327710931 hasLocation W23277109311 @default.
• W2327710931 hasOpenAccess W2327710931 @default.
• W2327710931 hasPrimaryLocation W23277109311 @default.
• W2327710931 isParatext "false" @default.
• W2327710931 isRetracted "false" @default.
• W2327710931 magId "2327710931" @default.
• W2327710931 workType "article" @default.